Skip to main content
Equibles
ESMC logo

ESMC · Escalon Medical Corp · Metrics

Track ESMC — free

Use ESMC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ESMC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.18 +0.01 (+7.65%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — cleared Oct 13, 2026

The latest filing states the doubt was alleviated.

“Management's assessment was further supported by several favorable developments during the year, including the resolution of the Company's prior going concern uncertainty and its return to a cumulative pre-tax income position.”
View the 10-K filed Oct 13, 2026
Market Cap
$1.36M
Shares
7.42M
Volume · Oct 19 5800 Avg daily vol (3M) 13.87K

ESMC metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.18
Market cap
$1.36M

Price action

20 metrics
Price change (1W)
+13.3%
Price change (30D)
-10.5%
Price change (3M)
-15.0%
Price change (6M)
+0.0%
Price change (YTD)
+0.0%
Price change (1Y)
+6.3%
Trailing year
Price change (5Y)
+6.3%
52-week high
$0.26
52-week low
$0.14
Change from 52-week high
-34.6%
Change from 52-week low
+21.4%
Annualized volatility
152.0%
Annualized volatility (3M)
—
Beta
3.0
RSI (14D)
50.2
Price vs SMA 50
-4.1%
Price vs SMA 200
-25.0%
Avg volume (3M)
13,769
Relative volume
5.1
Average dollar volume
$2,382

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
7.42M

Valuation

12 metrics
P / E (TTM)
0.6
Trailing earnings · reciprocal yield 158.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 938.5%
P / book
0.2
reciprocal yield 436.8%
FCF yield
-30.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
295.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
3.9×
reciprocal yield 25.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
43.7%
Operating margin
0.4%
Trailing 12 months
Net margin
31.5%
Gross profit (TTM)
$5.57M
Operating profit (TTM)
$45,235
Net income (TTM)
$4.01M
Trailing 12 months
Diluted EPS (TTM)
$0.27
FCF margin
-3.2%
Effective tax rate
-39.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.80

Growth

11 metrics
Revenue growth YoY
+50.2%
Year over year
Net income growth YoY
+3,702.5%
Revenue (TTM)
$12.74M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
+1.5%
Revenue CAGR (5Y)
+4.0%
EPS CAGR (3Y)
+108.0%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
67.7%
Return on assets
44.0%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
$67,823
Free cash flow (TTM)
−$407,025
Quick ratio
2.2
Interest coverage
6.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.07M
Total assets
$9.13M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$402,604
Capital expenditures (TTM)
$4,421
R&D (TTM)
$501,488
SG&A (TTM)
$5.02M
Stock compensation (TTM)
—
R&D / revenue
3.9%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 862668 CUSIP 296074305 Visit website